top of page

Browse by category

Search

GLP-1ra receptor agonists role in the management of obesity in Australia

GLP-1ra receptor agonists role in the management of obesity in Australia

GLP-1ra receptor agonists role in the management of obesity in Australia

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the...

Australia Increasing health burden of type 2 diabetes

Australia Increasing health burden of type 2 diabetes

Australia Increasing health burden of type 2 diabetes

The total number of people with type 2 diabetes in Australia tripled - from 379,532 to 1,307,261— between 1990 and 2019 and while people...

Anaemia leading causes of excess hospitalization for people with type 2 diabetes

Anaemia leading causes of excess hospitalization for people with type 2 diabetes

Anaemia leading causes of excess hospitalization for people with type 2 diabetes

Australian researchers have found that anaemia, mental health disorders and gastrointestinal disorders are leading reasons for excess...

Rates of obesity-related cancers in Australia quadrupled in a generation

Rates of obesity-related cancers in Australia quadrupled in a generation

Rates of obesity-related cancers in Australia quadrupled in a generation

Researchers at the Daffodil Center, a joint venture of Cancer Council NSW and the University of Sydney, have reported that the rate of...

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

Dec 19

Prescription drug monitoring needed post-MBS

Dec 17

Abdominal obesity and muscle loss increases the risk of death by 83% after age 50

Dec 15

Back to Top

bottom of page